NSCLC Stage IV Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Parallel, Pilot Study to Evaluate the Quality of Life Improvement of Oral Oligo Fucoidan as an Adjuvant in Subjects Receiving Platinum-based Chemotherapy With NSCLC
Primary Objectives:
To evaluate the Quality of Life (QoL) score of adding oral Oligo Fucoidan to platinum-based
chemotherapy in comparison with placebo in subjects with Non-Small Cell Lung Cancer (NSCLC).
Secondary Objectives:
To assess the progression-free survival (PFS) and objective response rate (ORR) of adding
oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects
with NSCLC.
This is a pilot, randomized, double-blind, multicenter study to evaluate the QoL score of
Oligo Fucoidan plus platinum-based chemotherapy versus placebo plus platinum-based
chemotherapy in subjects with NSCLC. Subjects will be randomized in a 1:1 ratio to receive
4.4 g BID of Oligo Fucoidan or placebo BID. Subject randomization will be stratified by NSCLC
disease stage (stage III and stage IV) and platinum-based drug (cisplatin and carboplatin).
This is a two-part study. The study treatment will be planned as follow:
1. Part I (Platinum-based Treatment Phase): Oligo Fucoidan/placebo in combination with 4~6
cycles of platinum-based chemotherapy;
2. Part II (Extension Phase): Continuous Oligo Fucoidan/placebo treatment after subject
completed platinum-based chemotherapy.
The total study treatment duration of investigational product from Part I to Part II will be
6 months.
Dosing of oral Oligo Fucoidan/placebo will begin on Study Day -2, 2 days prior to the start
of the platinum-based chemotherapy regimen, and will continue twice a day (BID) through the
following 6-months treatment period, which includes platinum-based treatment phase and
extension phase, if there's no treatment interruption. All subjects will receive
platinum-based IV infusion starting on Day 1 of each cycle, 3 weeks per cycle. Subjects will
continue to receive Oligo Fucoidan/placebo for 6 months until develop of treatment toxicity
which in the Investigator's opinion prohibits for further therapy, or until radiographic
progression of disease. Subjects who experience toxicities due to chemotherapy may require a
delay in the dosing schedule or a dose modification. Should a subject not receive
platinum-based chemotherapy on a scheduled cycle, a rescheduled cycle will be designated when
chemotherapy is reintroduced, but no more than 2 weeks delay.
The visit for subjects who have completed platinum-based treatment phase will be considered
as the End of Part I Visit (end of platinum-based treatment phase). The visit for subjects
who have completed 6-months treatment period (Part I & Part II) will be considered as the End
of Treatment (EOT) Visit. It is preferable that EOT Visit procedures will be conducted for
subjects prior to the initiation of another anticancer therapy.
Radiographic tumor assessments will be conducted at screening period, Cycle 4, End of
Platinum-based Treatment Phase, and EOT. Radiographic information will be collected according
to the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.
Toxicities will be graded at each study visit according to the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
Quality of life assessment as measured by the European Organization for Research and
Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) as well as health-related
quality of life questionnaire designed by the National Health Research Institutes (NHRI),
NHRI QLQ-TCM, based on traditional Chinese medicine (TCM) perspective. Both of them will be
performed at Study Day -2, Day 8 of Cycle 1, Day 1 of Cycle 3 & Cycle 5, and End of
Platinum-based Treatment Phase.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05543330 -
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04106180 -
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
|
Phase 2 | |
Recruiting |
NCT05215548 -
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT04042558 -
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
|
Phase 2 | |
Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
Recruiting |
NCT04467801 -
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
|
Phase 2 | |
Active, not recruiting |
NCT04027647 -
Phase 2 Study of Dacomitinib in NSCLC
|
Phase 2 | |
Recruiting |
NCT04768491 -
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
|
||
Not yet recruiting |
NCT04492969 -
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
|
||
Recruiting |
NCT04116918 -
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
|
||
Terminated |
NCT03411473 -
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
|
Phase 2 | |
Recruiting |
NCT03564197 -
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
|
N/A | |
Not yet recruiting |
NCT06219317 -
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT04604470 -
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
|
||
Recruiting |
NCT05132218 -
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
|
||
Not yet recruiting |
NCT04136535 -
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
|
Phase 2 | |
Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
Completed |
NCT06339554 -
Alectinib-induced Endocrine Toxicity
|
||
Active, not recruiting |
NCT04549428 -
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
|
Phase 2 | |
Recruiting |
NCT03647956 -
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
|
Phase 2 |